Evidence map›Paper›PMID 40650150›Full record

ReviewInternational journal of molecular sciences2025

Radiation Therapy Personalization in Cancer Treatment: Strategies and Perspectives.

Marco Calvaruso, Gaia Pucci, Cristiana Alberghina, Luigi Minafra

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Estimation of the α/β ratio for metastatic melanomas in a patient based on actual responses to radiation therapy delivered with various fractionation schedules.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Marco CalvarusoInstitute of Bioimaging and Complex Biological Systems-National Research Council (IBSBC-CNR), 90015 Cefalù, PA, Italy.ORCID 0000-0003-2387-8273
Gaia PucciInstitute of Bioimaging and Complex Biological Systems-National Research Council (IBSBC-CNR), 90015 Cefalù, PA, Italy.
Cristiana AlberghinaInstitute of Bioimaging and Complex Biological Systems-National Research Council (IBSBC-CNR), 90015 Cefalù, PA, Italy.
Luigi MinafraInstitute of Bioimaging and Complex Biological Systems-National Research Council (IBSBC-CNR), 90015 Cefalù, PA, Italy.ORCID 0000-0003-3112-4519

Funding

Unione europea- Next Generation EU, Missione 4 Componente 1, CUP B53D23020620006 - Ministero Italiano dell'Università e della Ricerca, PRIN 2022 Grant no. 2022PW8R47
6 · The paper itself

Abstract

Modern oncology increasingly relies on personalized strategies that aim to customize medical interventions, using both tumor biology and clinical features to enhance efficacy and minimize adverse effects. In recent years, precision medicine has been implemented as part of systemic therapies; however, its integration into radiation therapy (RT) is still a work in progress. Conventional RT treatment plans are based on the Linear Quadratic (LQ) model and utilize standardized alpha and beta ratios (α/β), which ignore the high variability in terms of treatment response between and within patients. Recent advances in radiobiology, as well as general medical technologies, have also driven a shift toward more tailored approaches, including in RT. This review provides an overview of current knowledge and future perspectives for the personalization of RT, highlighting the role of tumor and patient-specific biomarkers, advanced imaging techniques, and novel therapeutic approaches. As an alternative to conventional RT modalities, hadron therapy and Flash RT are discussed as innovative approaches with the potential to improve tumor targeting while sparing normal tissues. Furthermore, the synergistic combination of RT with immunotherapy is discussed as a potential strategy to support antitumor immune responses and overcome resistance. By integrating biological insights, technological innovation, and clinical expertise, personalized radiation therapy may significantly advance the precision oncology paradigm.

Indexed as

NeoplasmsPrecision MedicineRadiotherapyBiomarkers, TumorHumansImmunotherapyBiomarkers, Tumorpersonalized medicineradiobiologyradiotherapy

Identifiers

PMID40650150
PMCPMC12250120

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.